Top

Published in:

01-11-2010 | Movement Disorders - Short communication

Microglia activation is related to substantia nigra echogenicity

Authors: D. Berg, J. Godau, P. Riederer, M. Gerlach, T. Arzberger

Published in: Journal of Neural Transmission | Issue 11/2010

Abstract

Hyperechogenicity of the substantia nigra (SN) is a sensitive marker for Parkinson’s disease (PD). Previously, a relation between SN echogenicity and iron as well as neuromelanin content could be described in 60 human brains. In the present study on a subset of 33 brains, SN echogenicity was found to be correlated with microglia activation (ρ = 0.46, p = 0.008) after correction for iron and neuromelanin content. These findings strengthen the hypothesis of a close pathophysiological connection between SN hyperechogenicity and PD pathology.

Ben-Shachar D, Riederer P, Youdim MB (1991) Iron-melanin interaction and lipid peroxidation: implications for parkinson’s disease. J Neurochem 57(5):1609–1614CrossRefPubMed

Berg D, Grote C, Rausch WD, Maurer M, Wesemann W, Riederer P, Becker G (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25(6):901–904CrossRefPubMed

Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to parkinson’s disease. J Neurochem 79(2):225–236CrossRefPubMed

Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999–1005CrossRefPubMed

Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7(11):1044–1055CrossRefPubMed

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed

Connor JR, Boeshore KL, Benkovic SA, Menzies SL (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37(4):461–465. doi:10.1002/jnr.490370405 CrossRefPubMed

Fedorow H, Halliday GM, Rickert CH, Gerlach M, Riederer P, Double KL (2006) Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging 27(3):506–512CrossRefPubMed

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of parkinson’s disease: a prospective blinded study. Lancet Neurol 7(5):417–424CrossRefPubMed

Kaneko Y, Kitamoto T, Tateishi J, Yamaguchi K (1989) Ferritin immunohistochemistry as a marker for microglia. Acta Neuropathol 79(2):129–136CrossRefPubMed

Kazantsev AG, Kolchinsky AM (2008) Central role of alpha-synuclein oligomers in neurodegeneration in parkinson disease. Arch Neurol 65(12):1577–1581CrossRefPubMed

McGeer PL, McGeer EG (2008) Glial reactions in parkinson’s disease. Mov Disord 23(4):474–483CrossRefPubMed

Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660(1):8–18CrossRefPubMed

Radzun HJ, Hansmann ML, Heidebrecht HJ, Bodewadt-Radzun S, Wacker HH, Kreipe H, Lumbeck H, Hernandez C, Kuhn C, Parwaresch MR (1991) Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P. Lab Invest 65(3):306–315PubMed

Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208(1):1–25CrossRefPubMed

Tribl F, Asan E, Arzberger T, Tatschner T, Langenfeld E, Meyer HE, Bringmann G, Riederer P, Gerlach M, Marcus K (2009) Identification of l-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach. Mol Cell Proteomics 8(8):1832–1838. doi:10.1074/mcp.M900006-MCP200 CrossRefPubMed

Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76(6):1766–1773CrossRefPubMed

Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20(10):1278–1285CrossRefPubMed

Title: Microglia activation is related to substantia nigra echogenicity
Authors: D. Berg
J. Godau
P. Riederer
M. Gerlach
T. Arzberger
Publication date: 01-11-2010
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 11/2010
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-010-0504-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Microglia activation is related to substantia nigra echogenicity

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2010

The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis

Anticonvulsant action of 2-chloroadenosine against pentetrazol-induced seizures in immature rats is due to activation of A1 adenosine receptors

Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

Change in the expression of myelination/oligodendrocyte-related genes during puberty in the rat brain

Genetic TPH2 variants and the susceptibility for migraine: association of a TPH2 haplotype with migraine without aura

Subclinical Myasthenia Gravis causing increased sensitivity to botulinum toxin therapy